PRELUDE THERAPEUTICS INC
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $12.1M | $7.0M | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $94.3M | $118.0M | $103.4M | $92.9M | $86.8M | $48.2M | $24.3M |
| SG&A Expense | — | $22.4M | $28.7M | $28.9M | $30.7M | $27.0M | $10.6M | $3.8M |
| Operating Income | — | $-104.6M | $-139.7M | $-132.3M | $-123.5M | $-113.7M | $-58.8M | $-28.1M |
| Operating Margin | — | -861.3% | -1,995.9% | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | — | — | — | — | — |
| Net Income | — | $-99.5M | $-127.2M | $-121.8M | $-115.4M | $-111.7M | $-56.9M | $-27.6M |
| Net Margin | — | -819.6% | -1,816.8% | — | — | — | — | — |
| EPS (Basic) | — | $-1.29 | $-1.68 | $-2.02 | $-2.44 | $-2.43 | $-4.56 | $-16.52 |
| EPS (Diluted) | — | $-1.29 | $-1.68 | $-2.02 | $-2.44 | $-2.43 | $-4.56 | $-16.52 |
| Shares Outstanding (Basic) | 63.0M | 77.0M | 75.8M | 60.4M | 47.4M | 46.0M | — | — |
| Shares Outstanding (Diluted) | 63.0M | 77.0M | 75.8M | 60.4M | 47.4M | 46.0M | — | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |